IDEAYA is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. Founded in 2015, the Company has assembled a world-class drug discovery team and a Scientific Advisory Board (SAB) which consists of industry thought leaders including members of the National Academy of Sciences and the National Academy of Medicine. IDEAYA is headquartered in South San Francisco, California.